News for Adimmune Corporation (4142.TW)

— Clover’s

-- Clover’s leading respiratory vaccine franchise to be strengthened from commercial launch of quadrivalent influenza vaccine (AdimFlu-S [QIS]) in mainland...

Clover Provides Updates on Business and R&D Pipeline Development GlobeNewswire July 10, 2023 -- Clover’s leading respiratory vaccine franchise to be strengthened from commercial launch of quadrivalent influenza vaccine (AdimFlu-S [QIS]) in mainland China in H2-2023 --

— Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in…

-- Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues...

Clover Announces Corporate Updates and Full Year 2022 Financial Results GlobeNewswire March 28, 2023 -- Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in 2023 with continued growth thereafter -- 1 Compound annual growth rate (CGAR) based on influenza vaccine...

/PRNewswire/ -- The "Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029" & "Pharmaceutical Excipients Global Market - Forecast To 2029"...

— Clover to leverage its established and growing commercial infrastructure to exclusively distribute Adimmune’s AdimFlu-S (QIS), the only imported quadrivalent…

Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China GlobeNewswire February 19, 2023 -- Clover to leverage its established and growing commercial infrastructure to exclusively distribute Adimmune’s AdimFlu-S (QIS), the only imported quadrivalent influenza vaccine approved in mainland China -- 1 Sasha D, Valinsky L, Hershkowitz Sikron...